Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: Cancer Res. 2016 Oct 13;77(2):520–531. doi: 10.1158/0008-5472.CAN-16-1140

Figure 6. LD rapamycin improves DD treatment efficacy of B16F10 but not ID8agg tumors.

Figure 6

Mice challenged with 500,000 B16F10 cells on both flanks or with 4×106 ID8agg cells i.p. on day 0. (A) Top: B16 tumor growth, and bottom: survival of WT mice with control, LD rapamycin (75 μg/kg), DD or both. LD rapamycin administrated daily on days 7–15. DD (5 ug/mouse), starting on day 7, given every 5 days. P values for tumor growth, two-way ANOVA. Survival was analyzed by log-rank test. N= 10/group. (B) WT mice challenged with ID8agg-luciferase cells plus LD rapamycin (75 μg/kg), DD or both. LD rapamycin administrated daily on days 4–21. DD 5 μg, starting on day 7, given every 5 days until day 17. N=5/group. Arrows indicate DD administrations. Bracketed line encompasses rapamycin treatment dates. Bioluminescence detected following Luciferin injection IV.